The GLP-1 Revolution: Insights From Three Leading US Doctors

For one evening, join three leading US doctors who are at the forefront of the GLP-1 revolution. With 12% of the US population either currently using or having used a GLP-1 injectable, these experts will share their firsthand insights—what’s working, what’s not, and what the future holds for patients and practitioners alike.

Dr. Richard Goldfarb, MD, FACS: A board-certified surgeon with over 30 years of experience, Dr. Goldfarb is a leading expert in aesthetic medicine. At Melora Health & Enhancement in Pennsylvania, he specialises in non-surgical fat reduction, muscle enhancement, and anti-aging treatments using cutting-edge technology.

Dr. Ben Gonzalez, MD: Founder and Medical Director of Atlantis Medical Wellness Center, Dr. Gonzalez is a leader in Integrative and Functional Medicine with a focus on metabolic and obesity medicine. With expertise in weight management, hormone optimisation, and women’s health, he is a sought-after educator, teaching physicians nationwide how to integrate evidence-based and experience-based medicine into patient care.

Dr. Mark Tager, MD: A leading expert in healthcare communication, Dr. Tager is the Chief Enhancement Officer of ChangeWell, Inc. With a background in aesthetic, integrative, and regenerative medicine, he has helped shape the industry through innovative education and strategic consulting. He has authored 11 books and developed numerous educational programs for clinicians and consumers. Dr. Tager serves as faculty at Duke Integrative Medicine and continues to influence the fields of aesthetics and functional medicine through his work in education and professional development.

AND

Dr. Edward Walker, PhD: Based at The New Zealand Institute for Plant & Food Research, Dr. Walker is a scientist focusing on clinically validating nutraceutical products for human health applications. His work over the past 13 years has centered on plant-derived appetite suppressants, leading to the development of Amarasate®, the active ingredient in Calocurb, a hops-based ingredient that shares an overlapping mode of action with a new class of effective GLP-1-based anti-obesity drugs. Dr. Walker also lectures at the University of Auckland on nutraceuticals and functional foods, advocating for science-backed approaches to long-term wellness.